- Business Wire•18 hours agoAlnylam Presents Clinical and Non-Clinical Data Demonstrating Continued RNAi Platform Optimization and Leadership in the Development of RNA-Based Therapeutics at 12th Annual Meeting of the Oligonucleotide Therapeutics Society
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today new clinical and non-clinical research results demonstrating continued RNAi therapeutics platform innovation and optimization, including improved potency, durability, metabolic stability and tolerability with its GalNAc platform, as well as clinical translation across multiple pipeline programs.
- Business Wire•5 days agoAlnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today initial data from its ongoing Phase 1/2 study with ALN-GO1, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1 .
- Motley Fool•5 days ago
Both of these clinical-stage biotechs are big losers in 2016 so far. Which has the better chance of becoming a winner?
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||70.01 x 100|
|Ask||76.88 x 100|
|Day's Range||73.57 - 75.25|
|52wk Range||49.96 - 110.75|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-17.36|
|Avg Vol (3m)||653,364|
|Dividend & Yield||N/A (N/A)|